PMID- 27757041
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 9
DP  - 2016
TI  - Infliximab enhances the therapeutic effects of 5-fluorouracil resulting in tumor 
      regression in colon cancer.
PG  - 5999-6008
AB  - Colon cancer (CC) is among the most common malignant diseases with a dismal 
      survival. Tumor necrosis factor-alpha (TNF-alpha) has been identified as a 
      therapeutic target in various cancers, and anti-TNF-alpha treatment has shown 
      promising effects in different cancer models. However, if TNF-alpha can be targeted 
      in CC, the therapeutic values of anti-TNF-alpha treatment in CC remain unknown. Our 
      study indicated that TNF-alpha is highly expressed in CC cell lines and patient tumor 
      samples. High expression of TNF-alpha is an independent adverse prognosticator of CC. 
      Targeting the TNF-alpha by its antibody infliximab induced antibody-dependent 
      cellular cytotoxicity and complement-dependent cytotoxicity and enhanced 
      apoptosis leading to cell death. The combination of infliximab with 
      5-fluorouracil showed better responses in vitro and in vivo than 5-fluorouracil 
      alone. In conclusion, this study identified TNF-alpha as a target of CC and 
      anti-TNF-alpha treatment synergized with chemotherapy leading to a better outcome in 
      preclinical models.
FAU - Liu, Fen
AU  - Liu F
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, 
      Changsha, Hunan, People's Republic of China.
FAU - Ai, Feiyan
AU  - Ai F
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, 
      Changsha, Hunan, People's Republic of China.
FAU - Tian, Li
AU  - Tian L
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University.
FAU - Liu, Shaojun
AU  - Liu S
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University.
FAU - Zhao, Lian
AU  - Zhao L
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, 
      Changsha, Hunan, People's Republic of China.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, 
      Changsha, Hunan, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20161003
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5055041
OTO - NOTNLM
OT  - chemotherapy
OT  - colon cancer
OT  - prognosis
OT  - tumor necrosis factor-alpha
OT  - tumor regression
COIS- The authors report no conflicts of interest in this work.
EDAT- 2016/10/21 06:00
MHDA- 2016/10/21 06:01
PMCR- 2016/10/03
CRDT- 2016/10/21 06:00
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2016/10/21 06:01 [medline]
PHST- 2016/10/21 06:00 [entrez]
PHST- 2016/10/03 00:00 [pmc-release]
AID - ott-9-5999 [pii]
AID - 10.2147/OTT.S109342 [doi]
PST - epublish
SO  - Onco Targets Ther. 2016 Oct 3;9:5999-6008. doi: 10.2147/OTT.S109342. eCollection 
      2016.